Study on effect of metformin combined with risperidone in the treatment of schizophrenia with metabolic syndrome
Objective To study the clinical effect of metformin combined with risperidone in the treatment of schizophrenia with metabolic syndrome.Methods A total of 88 schizophrenic patients with metabolic syndrome were randomly divided into a control group and a study group,with 44 cases in each group.The control group was treated with risperidone,and the study group was treated with risperidone and metformin.Both groups were compared in terms of lipid metabolism indexes[total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C)],glucose metabolism indexes[fasting blood glucose(FBG),glycated hemoglobin(HbA1c),Hemostatic Model Assessment of Insulin Resistance Index(HOMA-IR)],Positive and Negative Symptom Scale(PANSS)score and quality of life score before and after treatment,and occurrence of adverse reactions.Results After treatment,TC,TG and LDL-C in the study group were(4.80±0.36),(2.42±0.52)and(2.10±0.37)mmol/L,which were lower than those of(5.04±0.45),(3.07±0.63)and(2.68±0.41)mmol/L in the control group,and the differences were statistically significant(P<0.05).After treatment,FBG,HbA1c and HOMA-IR in the study group were(6.83±1.15)mmol/L,(6.71±1.21)%and(5.45±0.89),which were lower than those of(8.43±1.49)mmol/L,(7.94±1.76)%and(6.97±0.96)in the control group,and the differences were statistically significant(P<0.05).After treatment,the scores of negative symptoms,positive symptoms and general psychopathology of the study group were(12.31±3.50),(16.10±4.06)and(13.15±2.40)points,which were lower than those of(15.61±4.53),(19.41±4.55)and(17.49±4.22)points of the control group.The differences were statistically significant(P<0.05).The scores of psychological function,independence,environmental adaptation and physiological function in the study group were(7.36±1.21),(7.63±2.31),(6.49±2.01)and(7.41±1.06)points,which were higher than those of(6.69±1.01),(6.74±1.37),(5.77±1.23)and(6.76±1.72)points in the control group,and the differences were statistically significant(P<0.05).The incidence of adverse reactions of 9.09%in the study group was significantly lower than that of 27.27%in the control group,and the differences were statistically significant(P<0.05).Conclusion In the treatment of schizophrenic patients with metabolic syndrome,the combination of metformin and risperidone can effectively improve the indicators of glucose and lipid metabolism in patients,which is conducive to alleviating the symptoms of schizophrenia,improving the quality of life,without causing serious adverse reactions,and ensuring the safety of treatment.
万方数据
维普
